T4	control 892 899	placebo
T7	total-participants 1188 1191	208
T8	age 1225 1235	44.6 years
T9	ethinicity 1246 1251	white
T12	outcome 1579 1607	mean change in serum 25(OH)D
T13	outcome 1650 1655	IGF-1
T14	iv-cont-mean 1471 1476	-0.3%
T15	cv-cont-mean 1481 1486	-1.2%
T16	iv-cont-mean 1524 1529	+1.5%
T17	cv-cont-mean 1534 1539	+1.6%
T18	iv-cont-mean 1611 1616	+18.9
T19	cv-cont-mean 1624 1634	+2.8 ng/mL
T20	iv-cont-mean 1659 1663	-9.8
T21	cv-cont-mean 1671 1681	-1.8 ng/mL
T1	intervention 73 98	Vitamin D Supplementation
T2	outcome 1430 1445	Mean MD changes
T3	outcome 1446 1465	at 12 and 24 months
T5	outcome-Measure 926 965	change in MD from baseline to 12 months
T10	eligibility 510 560	premenopausal women at high risk for breast cancer
T6	outcome-Measure 1024 1047	serial blood biomarkers
T11	outcome-Measure 1158 1160	MD
T22	outcome 1722 1724	MD
T23	outcome 1756 1767	serum IGF-1
T24	outcome 1772 1785	IGF-1/IGFBP-3
